A Multinational, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of FP 045 in Patients With Fanconi Anemia (FusuciA Study)

Description

This is a multi-center, Phase 1/2 study to determine the Optimal Biologic Dose (OBD) and to evaluate the safety, tolerability, PK, and preliminary activity of FP 045 when administered orally in young adult/adolescent and pediatric patients with Fanconi anemia. The study will enroll a total of 6 young adult/adolescent patients and a minimum of 8 and up to 12 pediatric patients with mild-moderate bone marrow failure who have not undergone hematopoietic cell transplant. This makes the total patient number between 14-18 total. Dose escalation will occur individually for each patient, within each age group. Each patient will receive each of 3 dose levels of FP 045 (intra-patient dose escalation), beginning with Dose Level 1, followed by Dose Levels 2 and 3. Each dose level will be administered for 28 days prior to escalation to the next higher dose level for that patient.Dose escalation will begin with young adult/adolescent patients. The initial two patients enrolled in the study will be \

Trial Eligibility

Inclusion Criteria: * male or female aged 3-25 * documented Fanconi anemia by chromosome breakage analysis * females of child-bearing potential and males required to use highly effective birth control * mild to moderate bone marrow failure with at least one cytopenia of \> grade 1 severity Exclusion Criteria: * history of any malignancy except focal squamous cell or basal cell carcinoma of the skin or carcinoma in situ of cervix * has myelodysplastic syndrome or acute leukemia per world health organization (WHO) criteria * has history of any significant medical conditions * has aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 5x upper limit of normal (ULN) or calculated creatinine clearance (Clcr) of \< 50 mL/min * has active Hepatitis B or C * has an ongoing systemic infection * requires a strong CYP3A4 inhibitor * has had major surgery within 30 days * Active graft versus host disease requiring systemic treatment * Has a history of bone marrow or stem cell transplant

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.